Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Targeted deletion of Vegfa in adult mice induces vision loss.

Authors: Kurihara, T  Westenskow, PD  Bravo, S  Aguilar, E  Friedlander, M 
Citation: Kurihara T, etal., J Clin Invest. 2012 Nov;122(11):4213-7. doi: 10.1172/JCI65157. Epub 2012 Oct 24.
Pubmed: (View Article at PubMed) PMID:23093773
DOI: Full-text: DOI:10.1172/JCI65157

Current therapies directed at controlling vascular abnormalities in cancers and neovascular eye diseases target VEGF and can slow the progression of these diseases. While the critical role of VEGF in development has been well described, the function of locally synthesized VEGF in the adult eye is incompletely understood. Here, we show that conditionally knocking out Vegfa in adult mouse retinal pigmented epithelial (RPE) cells, which regulate retinal homeostasis, rapidly leads to vision loss and ablation of the choriocapillaris, the major blood supply for the outer retina and photoreceptor cells. This deletion also caused rapid dysfunction of cone photoreceptors, the cells responsible for fine visual acuity and color vision. Furthermore, Vegfa deletion showed significant downregulation of multiple angiogenic genes in both physiological and pathological states, whereas the deletion of the upstream regulatory transcriptional factors HIFs did not affect the physiological expressions of angiogenic genes. These results suggest that endogenous VEGF provides critical trophic support necessary for retinal function. Targeting factors upstream of VEGF, such as HIFs, may be therapeutically advantageous compared with more potent and selective VEGF antagonists, which may have more off-target inhibitory trophic effects.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11075234
Created: 2016-05-10
Species: All species
Last Modified: 2016-05-10
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.